Processa Pharmaceuticals is acquiring Vidya Therapeutics in an all-stock deal that gives it a clinical-stage oral BTK inhibitor and sets up a future challenge to a newly approved Novartis drug.

What BTK inhibitors do

Bruton’s tyrosine kinase (BTK) is an enzyme that acts as a central relay in immune cells — especially B cells and mast cells — that drive many inflammatory and allergic conditions. BTK inhibitors first made their mark in blood cancers (drugs like ibrutinib), but the class is now expanding into immunology, where dialing down BTK signaling could calm the overactive immune responses behind allergies, hives and autoimmune disease.

The deal

Announced July 29, 2026 and expected to close July 31, the transaction centers on VT-7208, an oral small-molecule BTK inhibitor. Alongside it, Processa is raising $200 million in a concurrent private placement — a substantial cushion for a company that reported just $1.7 million in cash at the end of the first quarter. Management says the financing extends its runway into the second half of 2029, buying time to run trials.

What makes VT-7208 different

Processa is positioning VT-7208 as a differentiated, next-generation BTK inhibitor: once-daily dosing, brain-penetrating properties (relevant for neurological conditions), and a design intended to minimize the off-target effects that can raise the risk of liver complications — a known concern for the class. The company plans to test it across food allergy, chronic spontaneous urticaria (CSU), relapsing multiple sclerosis, and rare inflammatory skin disorders such as hidradenitis suppurativa and chronic inducible urticaria.

The Novartis benchmark

The obvious comparison is Novartis’s Rhapsido (remibrutinib), the first BTK inhibitor approved for an immunological indication — cleared in October 2025 for chronic spontaneous urticaria. Rhapsido is dosed twice daily; Processa is betting a once-daily, brain-penetrating profile could carve out room in this fast-emerging class.

What comes next

Processa laid out an ambitious calendar: Phase 2 studies in food allergy and CSU are slated for the second half of 2026, with food-allergy data expected in late 2027 and CSU data in early 2028; a Phase 2 multiple sclerosis study is planned for the first half of 2027, with data in late 2028. As with any early pipeline, those readouts — not the deal itself — will decide whether the bet pays off. Business news, not investment advice.